Thus, our investigation provided a novel clue for clarifying the molecular mechanism involved in disease progression and response to chemotherapeutic drugs in HCC, which indicated an optional therapeutic strategy for HCC treatment by modulating NOD2/AMPK signaling axis. The gene discussed is NOD2; the disease is hepatocellular carcinoma.